Viking Therapeutics (VKTX)
36.39
-0.92 (2.47%)
Upcoming Events
Latest Headlines
Viking Therapeutics adds Dorothy Gemmell to its board of directors
July 23, 2026 7:05 AM - StreetInsider
Viking Therapeutics Appoints Dorothy Gemmell to Board of Directors
July 23, 2026 7:05 AM - PR NewsWire
Viking Therapeutics to Report Financial Results for Second Quarter 2026 on July 29, 2026
July 22, 2026 4:05 PM - PR NewsWire
Piper Sandler Reiterates Overweight Rating on Viking Therapeutic (VKTX)
July 7, 2026 7:52 AM - StreetInsider
Viking Therapeutic (VKTX) Reiterated at Overweight by Cantor Fitzgerald
July 1, 2026 7:03 AM - StreetInsider
Viking Therapeutics starts Phase 1 trial of weight loss drug VK3019
June 24, 2026 7:05 AM - StreetInsider
Viking Therapeutics Announces Initiation of Phase 1 Study to Evaluate Novel Amylin Receptor Agonist VK3019 in Healthy Adults
June 24, 2026 7:05 AM - PR NewsWire
Viking Therapeutics names Hubert Chen as chief medical officer
June 11, 2026 7:05 AM - StreetInsider
Viking Therapeutics Announces Appointment of Hubert C. Chen, M.D., as Chief Medical Officer
June 11, 2026 7:05 AM - PR NewsWire
Oral GLP-1 obesity drugs see rapid early adoption, Bernstein survey shows
June 9, 2026 2:31 PM - StreetInsider
Form 4 Viking Therapeutics, For: Jun 01 Filed by: Chen Hubert C
June 3, 2026 7:45 PM - SEC Filing
Form 3 Viking Therapeutics, For: Jun 01 Filed by: Chen Hubert C
June 3, 2026 7:44 PM - SEC Filing
Lake Street Starts Viking Therapeutic (VKTX) at Buy
May 28, 2026 7:38 AM - StreetInsider
Truist Securities Assumes Viking Therapeutic (VKTX) at Buy
May 27, 2026 6:08 AM - StreetInsider
Form 8-K Viking Therapeutics, For: May 19
May 26, 2026 4:48 PM - SEC Filing
Viking Therapeutics to Participate at Upcoming Investor Conferences
May 21, 2026 7:05 AM - PR NewsWire
Next-Generation GLP-1 Innovation Could Unlock Massive Metabolic Healthcare Market Opportunities
May 13, 2026 8:33 AM - StreetInsider
Viking Therapeutics presents obesity drug trial results at conference
May 12, 2026 7:05 AM - StreetInsider
Viking Therapeutics Presents Data from its 13-Week Phase 2 VENTURE-Oral Dosing Trial of VK2735 at European Congress on Obesity (ECO) 2026
May 12, 2026 7:05 AM - PR NewsWire
Viking Therapeutics Announces Two Poster Presentations at European Congress on Obesity (ECO) 2026
May 5, 2026 7:05 AM - PR NewsWire
Form SCHEDULE 13G Viking Therapeutics, Filed by: VANGUARD CAPITAL MANAGEMENT LLC
April 30, 2026 2:22 PM - SEC Filing
Viking Therapeutic (VKTX) PT Lowered to $95 at Morgan Stanley
April 30, 2026 7:59 AM - StreetInsider
Form 10-Q Viking Therapeutics, For: Mar 31
April 30, 2026 6:14 AM - SEC Filing
Viking Therapeutics (VKTX) Misses Q1 EPS by 35c
April 29, 2026 4:16 PM - StreetInsider
Form 8-K Viking Therapeutics, For: Apr 29
April 29, 2026 4:06 PM - SEC Filing
Viking Therapeutics Reports First Quarter 2026 Financial Results and Provides Corporate Update
April 29, 2026 4:05 PM - PR NewsWire
Raymond James on Viking Therapeutic (VKTX): 'Our analysis of this dataset suggests semaglutide does not have a lean body mass preservation advantage'
April 24, 2026 6:36 AM - StreetInsider
Full Article List
